Cytek IPO Presentation Deck

Disclaimer Cytek Biosciences, Inc. (the "Cytek," "we," "us," or "our") has filed a registration statement on Form S-1 (File No. 333-257663) including a preliminary prospectus with the Securities and Exchange Commission (the "SEC") in connection with the proposed offering to which this presentation relates. Such registration statement has not yet become effective as of the time of this presentation. Before you invest, you should read the prospectus and the other documents Cytek files with the SEC for more complete information about Cytek and the proposed offering. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Cytek, any underwriter or any dealer participating in the offering can arrange to send you the prospectus if you request a copy by calling Morgan Stanley & Co. LLC at 866-718-1649 or emailing at [email protected]; Goldman Sachs & Co. LLC at 866-471-2526 or emailing at [email protected]; Piper Sandler & Co. at 800-747-3924 or emailing at [email protected]; or Cowen and Company, LLC at 833-297-2926 or emailing at [email protected]. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. By accepting this information, each recipient agrees that (i) no portion of this presentation may be reproduced or distributed in any format without Cytek's prior express written consent, (ii) it will not copy, reproduce or distribute this presentation, in whole or in part, to any person or party, and (ii) it will use this presentation for the sole purpose of evaluating Cytek. This presentation does not purport to contain all of the information that may be required to evaluate Cytek. This presentation is not intended to form the basis of any investment decision by the recipient and does not constitute investment, tax or legal advice. CYTEK MAKES NO EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY AS TO THE ACCURACY OR COMPLETENESS OF THE INFORMATION CONTAINED HEREIN. CYTEK EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY THAT MAY BE BASED ON ANY INFORMATION SET FORTH IN THIS PRESENTATION, ERRORS THEREIN OR OMISSIONS THEREFROM. YOU SHALL MAKE AN ASSESSMENT OF CYTEK AND ITS SECURITIES INDEPENDENTLY AND WITHOUT RELIANCE EXCLUSIVELY UPON THIS PRESENTATION. This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. All statements other than statements of historical facts contained in this presentations presentation, including, without limitation, statements regarding the cell analysis market and our revenue growth and other GAAP and non GAAP financial metrics, our future results of operations and financial position, our business strategy, prospective products, total addressable market, customer mix, collaborations, plans and objectives of management for future operations, and future results of current and anticipated products are forward looking statements. The words "may," "will, "expect," "anticipate," "aim," "estimate." "intend," "plan," "believe," "is/are likely to." "potential," "continue" and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this presentation are only predictions and represent our views as of the date of this presentation. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. The forward-looking statements are subject to a number of risks, uncertainties and assumptions. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We operate in a very competitive and rapidly changing environment. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements contained in this presentation. There can be no assurance that the opportunity will meet your investment objectives or that you will receive a return of all or part of such investment. Investment results may vary significantly over any given time period. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. We recommend that investors independently evaluate specific investments and strategies. This presentation contains Adjusted EBITDA, a financial measure that is not in accordance with Generally Accepted Accounting Principles (GAAP). Reconciliations of Adjusted EBITDA to the most comparable GAAP measure are included at the end of this slide presentation. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance. Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Cytek's own internal estimates and research. While Cytek believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources. While Cytek believes its internal research is reliable, such research has not been verified by any independent source. Cytek's estimates are derived from publicly available information, management's knowledge of the Cytek's industry and management's assumptions based on such information and knowledge, which they believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. Cytek is a trademark that we own. Other trademarks appearing in this presentation are the property of their respective holders. This presentation contains information that is highly confidential and/or highly privileged. The information is intended only for the use of individuals or entities to which it is addressed. By agreeing to attend this meeting, you agree to keep all such information and the fact that this meeting has taken place confidential. If you are not the intended recipient, you are hereby notified that any reliance, disclosure, copying, distribution, or taking of any action on the contents of this material is strictly prohibited. CYTEK 2